Payer pushback aside, Sovaldi, and so Gilead, has another huge quarter

Eric Palmer

Sciences' juggernaut, , keeps on rolling along despite the from payers, politicians and health officials over the high price of the hepatitis C cure. It racked up $ 3.5 billion sales in the second , on top of the nearly $ 2.3 billion in the first, a sum that made it the fastest drug launch ever.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS